Edison Initiates Coverage on Midatech

LONDON, June 24, 2015 /PRNewswire/ --

Edison Investment Research, a leading international investment research firm, announces the initiation of full coverage of Midatech 

     (Logo: http://photos.prnewswire.com/prnh/20130417/608168 )

Highlights of the analysis on Midatech by Edison's pharma & biotech analysts Franc Gregori and Christian Glennie are as follows:

Midatech is an ambitious speciality pharmaceutical company founded in 2000. The patented gold nanoparticle technology platform is developing therapeutics for several diseases such as diabetes and various cancers. A microsphere platform ensures predictable engineering of micro-particles.

Midatech can currently be viewed as a drug development company and best suited to an rNPV methodology. Our valuation of £134.7m (485p share) is based on a risk-adjusted model of the development programmes alone, with no contribution for the value of the technology platforms or production facilities. Continued progress would result in further upside to our valuation. The company had cash of £30.3m at end-FY14, which allows it to operate through to a number of value-inflection points.

To download this report, please click here.

All reports published by Edison are available to download free of charge from its website http://www.edisongroup.com.

About Edison: Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals works with leading companies, fund managers and investment banks worldwide to support their capital markets activities. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (http://www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584).

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information please contact:
Franc Gregori
Edison Investment Research
+44(0)20-3077-5728

Christian Glennie
Edison Investment Research
+44(0)20-3077-5727
[email protected]

Contact details: Learn more at http://www.edisongroup.com and connect with Edison on:  

LinkedIn: http://www.linkedin.com/company/edison-investment-research
Twitter: http://www.twitter.com/Edison_Inv_Res
YouTube: http://www.youtube.com/edisonitv

SOURCE Edison Investment Research

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED